10-Q: Chemours Reports Q3 Loss Amidst PFAS Settlements, Operational Headwinds

Chemours reported a net loss of $325 million for the first nine months of 2025, driven by significant PFAS litigation settlements and operational challenges in its Titanium Technologies and Advanced Performance Materials segments.

Summary

• Net loss attributable to Chemours was $325 million for the nine months ended September 30, 2025, compared to net income of $81 million for the same period in 2024.
• Net sales increased by 1% to $4.478 billion for the nine months ended September 30, 2025, but decreased by 1% to $1.495 billion for the three months ended September 30, 2025.
• Litigation-related charges for the nine months ended September 30, 2025, totaled $301 million, primarily due to a $263 million accrual for the New Jersey PFAS settlement.
• Environmental charges for the nine months ended September 30, 2025, were $73 million, mainly from changes in remediation reserves at sites covered by the New Jersey settlement.
• Thermal & Specialized Solutions segment net sales increased by 13% for the nine months and 20% for the three months, driven by Opteon™ Refrigerant demand.
• Titanium Technologies segment net sales decreased by 4% for the nine months and 9% for the three months, due to price and volume declines.
• Advanced Performance Materials segment net sales decreased by 5% for the nine months and 12% for the three months, impacted by operational outages and market weakness.
• The company recorded a $56 million goodwill impairment charge in the Advanced Performance Materials segment for the nine months ended September 30, 2024.
• An Audit Committee internal review in Q1 2024 found violations of the Code of Ethics by the then CEO, CFO, and Controller.
• The U.S. federal government shutdown, effective October 1, 2025, could cause delays in regulatory approvals and payments.

Sentiment

Score: 3

Explanation: The company reported a significant net loss for the nine-month period, primarily driven by substantial PFAS litigation settlements and environmental charges. While the Thermal & Specialized Solutions segment showed growth, the Titanium Technologies and Advanced Performance Materials segments faced declines and operational disruptions. The ongoing legal and regulatory uncertainties surrounding PFAS, coupled with the U.S. government shutdown and management ethics violations, present considerable headwinds and risks to future financial performance and reputation.

Positives

• Thermal & Specialized Solutions segment net sales increased by $181 million (13%) for the nine months ended September 30, 2025, and $92 million (20%) for the three months, driven by stronger Opteon™ Refrigerant demand and stationary AC regulatory transition.
• Thermal & Specialized Solutions Segment Adjusted EBITDA increased by $93 million (21%) for the nine months and $55 million (40%) for the three months ended September 30, 2025.
• The company entered into a strategic agreement with SRF Limited to strengthen its global supply chain for fluoropolymers and fluoroelastomers, requiring no upfront capital investment.
• A $45 million settlement agreement was reached with an insurance carrier for PFAS matters in July 2024, with Chemours receiving approximately $23 million.
• The maturity date of the $1,050 million senior secured U.S. Dollar Term Loan was extended from August 18, 2028, to October 15, 2032.
• The company believes it has sufficient liquidity through future cash flows, unrestricted cash ($613 million), and its revolving credit facility ($953 million available) to settle current liabilities through at least November 2026.
• The company is on track to achieve its estimated goal of 350 million tons of avoided carbon dioxide equivalent emissions by the end of 2025 through low GWP products.

Negatives

• Net loss attributable to Chemours was $325 million for the nine months ended September 30, 2025, a significant decline from net income of $81 million in the prior year.
• Net sales decreased by $13 million (1%) for the three months ended September 30, 2025, primarily due to a 3% decrease in volume.
• Titanium Technologies segment net sales decreased by $73 million (4%) for the nine months and $60 million (9%) for the three months ended September 30, 2025, due to price and volume declines and operational disruption costs.
• Advanced Performance Materials segment net sales decreased by $50 million (5%) for the nine months and $43 million (12%) for the three months ended September 30, 2025, due to volume decreases from operational impacts and weakness in cyclical end markets.
• Advanced Performance Materials Segment Adjusted EBITDA decreased by $17 million (15%) for the nine months and $24 million (63%) for the three months ended September 30, 2025, significantly impacted by a $20 million outage at the Washington Works site in Q3.
• Cost of goods sold increased by $186 million (5%) for the nine months and $40 million (3%) for the three months ended September 30, 2025, primarily due to higher raw materials costs.
• Selling, general, and administrative (SG&A) expense increased by $241 million (56%) for the nine months ended September 30, 2025, primarily due to $263 million in litigation-related charges for the New Jersey PFAS settlement.
• A $56 million non-cash goodwill impairment charge was recognized in the Advanced Performance Materials segment for the three and nine months ended September 30, 2024.
• The company recorded a $148 million tax expense for a valuation allowance against deferred tax assets for U.S. federal and state interest carryforwards for the nine months ended September 30, 2025.
• The company paid a penalty of €1 million to the Dutch ILT agency in June 2025 related to F-gas reporting.
• The European Commission imposed a 200% F-gas quota reduction penalty applicable in 2026 due to quota exceedance.

Risks

• Adverse resolution of one or more legal or environmental matters could have a material adverse effect on liquidity.
• Disputes between Chemours and EID regarding indemnification matters could materially adversely affect the company.
• Inherent uncertainties in legal and regulatory processes in multiple jurisdictions mean management's judgments may differ materially from actual outcomes, potentially leading to losses substantially in excess of accrued liabilities.
• The company is subject to various lawsuits, claims, assessments, government investigations, and regulatory proceedings related to product liability, intellectual property, personal injury, commercial, contractual, employment, regulatory, environmental, anti-trust, and other matters.
• Potential governmental, criminal, or civil proceedings related to PFAS could result in fines, penalties, and/or other remedies, with duration, scope, or result currently unpredictable.
• The U.S. federal government shutdown could result in delays in regulatory approvals, permitting, environmental remediation, and payments under government contracts, potentially affecting financial condition, results of operations, and cash flows.
• The long-term impact of tariffs on the chemicals sector and the company's business, financial condition, and results of operations remains uncertain.
• Continued adverse trends in the global TiO2 and hydrogen-related markets could negatively affect expected profitability and future cash-flow forecasts, potentially requiring future impairment tests.
• Costs to comply with complex environmental laws and regulations are significant and may become more stringent, leading to additional compliance costs, increased raw material/energy costs, or operational restrictions.
• One or more manufacturing processes, key raw materials, or products may be found to have, or be characterized or perceived as having, a toxicological or health-related impact, leading to liability, increased costs, recalls, phase-outs, or bans.
• The estimated liabilities of achieving Consent Order and Addendum objectives at Fayetteville may vary significantly and exceed recorded reserve estimates.
• Issues relating to site discharges, remediation alternatives, or operating effectiveness of the thermal oxidizer at Fayetteville could result in further litigation or regulatory demands.
• The outcome of technical evaluations in the New Jersey RFS review process could lead to additional required remediation activities and future changes to environmental reserve estimates.
• The timing of remaining TSCA test orders for PFAS compounds is not determinable, and additional costs could be incurred.
• The EU REACH restriction proposal for PFAS, including F-gases and fluoropolymers, could lead to a full ban or time-limited derogations, with estimated earliest entry into force in 2027, potentially having material adverse effects.
• New F-Gas reporting and quota consumption regulations in the EU could impact the company.
• The proposed hazard classification of trifluoroacetic acid (TFA) as a Category 1B reproductive toxicant and PMT/vPvM could lead to legally binding changes across the EU after a transition period.
• The ultimate outcome of EPA's actions regarding PFAS (NPDWR, CERCLA designation) could increase environmental remediation liabilities and accrued litigation, materially affecting results.
• The West Virginia Rivers Coalition lawsuit against Washington Works for CWA violations and the preliminary injunction on HFPO-DA discharge limits pose ongoing legal and operational risks.

Future Outlook

The company anticipates generating additional positive cash flows from operations in 2025 and believes it has sufficient liquidity to fund operations and meet obligations through at least November 2026. However, the ultimate costs for environmental remediation and PFAS litigation remain uncertain and could materially increase. The company is evaluating the impact of the U.S. Tax Act for future tax years and continues to monitor macroeconomic and industry-specific conditions, particularly in the TiO2 and hydrogen markets, for potential future impairment risks. Regulatory changes in the EU regarding PFAS and F-gases are expected to lead to restrictions, with the earliest entry into force estimated for 2027, potentially impacting the company's operations and marketability of products. The U.S. federal government shutdown could also cause delays in regulatory approvals and payments.

Management Comments

• "We are a different kind of chemistry company. Our world-class product portfolio enables the performance and convenience of everyday products, processes, and technologies people rely on in their daily lives, making our products and the solutions they enable both vital and essential."
• "We are committed to creating value for our customers and stakeholders by leveraging strengths that we use to create competitive advantage: our innovation and technical expertise, our ability to operate complex manufacturing sites safely, our deep customer relationships based on trust and reliability, and our talented workforce."
• "Our core values, in unison with our company vision of Trusted Chemistry, helping people live better lives and communities thrive, underpin our commitment to our stakeholders. Our values and vision cannot be separated from our business strategy."
• "At Chemours, our approach to Sustainability begins with our vision to deliver Trusted Chemistry that helps people live better lives and communities to thrive."
• "We understand that maintaining safe, sustainable operations has an impact on us, our communities, the environment, and our collective future."
• "We are committed to continue working with policymakers, our value chain, and other organizations to find solutions that meet science-based regulations and address community needs."
• "Management believes the Company's accounting treatment and disclosure for the matters discussed below are appropriate based on the facts and circumstances for each matter."
• "Management believes that it is reasonably possible that the Company could incur losses related to PFOA and/or PFAS matters in excess of amounts accrued, but any such losses, which could be material to results of operations, financial position, or cash flows are not estimable at this time."
• "Management does not believe that any loss, in excess of amounts accrued, related to remediation activities at any individual site will have a material impact on our financial position or cash flows for any given year, as such obligation can be satisfied or settled over many years."
• "Based on available information, we do not believe the above matter [Dordrecht F-gas conditional fine] will have a material impact on our financial position, results of operation or cash flows."

Industry Context

The chemicals sector is facing significant regulatory changes, particularly concerning PFAS and HFCs, with global regulations like the U.S. AIM Act and EU F-Gas Directive driving a phase-down of high global warming potential refrigerants, creating opportunities for low GWP products like Opteon™. However, the industry is also grappling with broad PFAS restrictions proposed by ECHA, which could impact a wide range of fluorinated substances. The global TiO2 market continues to experience sustained weakness, affecting pricing and utilization levels. Delays in hydrogen-related infrastructure development are impacting certain end markets for advanced materials. Tariffs and a U.S. federal government shutdown add further uncertainty to the operating environment.

Management Changes

Corporate Governance

Legal Proceedings

• PFAS Litigation: Proposed Judicial Consent Order (JCO) with State of New Jersey to resolve all statewide PFAS claims and legacy contamination claims at four operating sites (Chambers Works, Parlin, Pompton Lakes, Repauno). Total payments of $875 million over 25 years, with Chemours contributing 50% ($263 million NPV).
• PFAS Litigation: Settlement agreement with State of Ohio for $55 million (Chemours' 50% share) for environmental releases or sales of PFAS.
• PFAS Litigation: Supplemental payment of $13 million (Chemours' share) to the State of Delaware Trust for PFAS-related natural resource damages.
• PFAS Litigation: Approximately 11,100 matters involving Aqueous Film Forming Foam (AFFF) in South Carolina federal court. Public water system class action settled for $1.185 billion (Chemours contributed $592 million). Ongoing discovery in personal injury cases (approx. 10,200) and product identification in real property cases. Significant number of new personal injury claims filed or transferred to AFFF MDL since August 2025 case management orders.
• PFAS Litigation: Agreement in principle to resolve Hoosick Falls class action for $27 million total, Chemours' portion $13.5 million.
• PFAS Litigation: Court ruled defendants liable for PFOA emissions and removal costs if deposited emissions infringe property rights in Netherlands municipalities case. LOI signed for remediation plan and further settlement discussions.
• PFAS Litigation: West Virginia Rivers Coalition filed Clean Water Act complaint alleging effluent discharge limit exceedances at Washington Works. Preliminary injunction issued in August 2025 enjoining HFPO-DA discharge above limits.
• PFAS Litigation: Refiled putative national class action (Hardwick) in Ohio federal court seeking medical monitoring for PFAS in blood serum.
• PFAS Litigation: Numerous lawsuits filed by water suppliers in New York, Georgia, Alabama, and other states alleging PFAS contamination, seeking damages and injunctive relief. Many opted out of the national settlement.
• PFAS Litigation: Multiple lawsuits alleging personal injury (e.g., cancer) from PFAS exposure in firefighter turnout gear.
• PFAS Litigation: Lawsuits in Georgia and Alabama alleging PFAS contamination from carpet/textile manufacturing waste.
• PFAS Litigation: Majority of U.S. states and territories investigating or suing for PFAS contamination of natural resources.
• Asbestos Litigation: Approximately 833 lawsuits pending against EID (assigned to Chemours) alleging personal injury from asbestos exposure. Settlement agreement in March 2025 for SGPI asbestos cases, Chemours assumed approx. 20 current and all future SGPI claims. Accruals of $90 million at September 30, 2025.
• Benzene Litigation: 22 cases pending against EID (assigned to Chemours) alleging benzene-related illnesses. Insurance coverage litigation with settlements negotiated.
• U.S. Smelter and Lead Refinery, Inc.: Five lawsuits pending in Indiana federal court concerning Superfund site, alleging Chemours responsible for EID environmental liabilities.
• Securities Related Litigation: Two putative class actions filed in Delaware federal court against the company and former officers alleging violations of Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 and SEC Rule 10b-5.
• Stockholder Derivative Actions: Two actions filed in Delaware state court against the company, former officers, and past/current board members alleging breach of fiduciary duty and unjust enrichment (consolidated and stayed). A third action filed in June 2025 also consolidated and stayed.
• Government Investigations: Cooperation with SEC and U.S. Attorneys Office for Southern District of New York concerning Audit Committee Internal Review results and SEC filings. Grand jury subpoena received in July 2020 regarding PFAS and food contact applications.
• Dordrecht Criminal Complaint: Dutch criminal defense lawyer announced criminal complaint with support of citizens against Chemours and its current and former directors for alleged unlawful emissions of PFOA and GenX.
• Dordrecht F-gas Penalties: €1 million penalty paid to Dutch ILT agency in June 2025 for F-gas reporting. European Commission imposed a 200% quota reduction penalty applicable in 2026 due to quota exceedance, which Chemours is appealing.

Related Party Transactions

• Memorandum of Understanding (MOU) with DuPont, Corteva, and EID for cost-sharing of legacy PFAS liabilities (Chemours bears 50%, DuPont and Corteva 50% up to $4 billion aggregate).
• PFAS Insurance Proceeds Memorandum of Understanding (PFAS Insurance MOU) with DuPont and Corteva, where Chemours assigned rights to certain insurance proceeds for $150 million consideration to fund NJ settlement.
• Net sales to equity method investees amounted to $104 million for the nine months ended September 30, 2025.
• Purchases from equity method investees amounted to $216 million for the nine months ended September 30, 2025.
• Dividends received from equity method investees amounted to $3 million for the nine months ended September 30, 2025.
• Indemnification and expense advancement obligations to current and former senior management and directors.
• Intercompany transactions and balances among the Parent Issuer and Guarantor Subsidiaries, and Non-Guarantor Subsidiaries.

Stakeholder Impact

• Shareholders: Significant net loss and ongoing litigation liabilities could negatively impact shareholder value and future dividends. Securities litigation and derivative actions directly target shareholder interests.
• Employees: Restructuring programs (SPS Capstone™ Exit, 2024 Restructuring Program, Titanium Technologies Transformation Plan) involve employee separation charges. Management ethics violations could impact employee morale and trust.
• Customers: Operational disruptions (e.g., Washington Works outage) and regulatory changes (e.g., PFAS restrictions, F-gas phase-down) could affect product supply and availability. Demand for Opteon™ refrigerants is a positive.
• Communities: Environmental remediation activities and PFAS contamination issues directly impact communities near manufacturing sites (e.g., Fayetteville, Dordrecht, Chambers Works, Pompton Lakes, Washington Works). Settlements aim to address community concerns and environmental restoration.
• Creditors: Increased debt and significant liabilities could impact credit ratings and borrowing costs, though liquidity is currently deemed sufficient.

Next Steps

• Continue to work with EPA, NJ DEP, and other authorities regarding required work for PFOA matters.
• Evaluate medical panel recommendations to modify the Leach Settlement medical monitoring program.
• Engage in discussions for potential resolution of personal injury cases in the AFFF MDL.
• Further evaluate new personal injury claims and submitted information in the AFFF MDL.
• Proceed with product identification discovery on a selection of 12 real property cases in the AFFF MDL.
• Continue to implement abatement technology to reduce discharges below conditional fine levels at Dordrecht Works.
• Engage with regulatory authorities on the revised permit application for Dordrecht Works.
• Appeal the preliminary injunction order from the West Virginia federal court regarding HFPO-DA discharge at Washington Works.
• Seek appeal of the summary judgment on liability for nuisance and trespass in the Fayetteville litigation (Cumberland County, NC).
• Work with NJ DEP and potentially LSRPs to determine appropriate RFS amounts and review future scope of remediation for the four New Jersey sites.
• Continue to evaluate the impact of the U.S. Tax Act for future tax years.
• Monitor macroeconomic and industry-specific conditions for indicators of potential impairment of goodwill and long-lived assets.
• Continue to evaluate the potential impact of new F-Gas reporting and quota consumption regulations.
• Monitor the EU REACH restriction process for PFAS, with further meetings of RAC and SEAC in 2025.
• The European Commission will publish a report on the effects of the new HFC regulation no later than January 1, 2030.
• The EU Commission will review the RAC's opinion on TFA hazard classification and determine whether to amend the CLP regulation.
• The company expects to receive future TSCA test orders for PFAS compounds.
• The company expects to make additional cash contributions of $1 million to its defined benefit pension plans during the remainder of 2025.
• The company expects to pay amounts related to the State of Ohio settlement in Q4 2025 and State of Delaware supplemental payment in H1 2026.
• The first annual payment under the New Jersey PFAS settlement is due within 30 days of JCO entry, no earlier than January 31, 2026.

Key Dates

Recommendation

The company reported a substantial net loss for the nine months ended September 30, 2025, primarily driven by significant PFAS litigation settlements and environmental charges. While the Thermal & Specialized Solutions segment shows some strength, the core Titanium Technologies and Advanced Performance Materials segments are experiencing declining sales and profitability due to market weakness and operational disruptions. The ongoing and extensive PFAS litigation, including the $875 million New Jersey settlement, represents a material and long-term financial burden. Furthermore, the disclosure of ethics violations by former senior management, coupled with related securities and derivative litigation, raises serious corporate governance concerns and potential reputational damage. The uncertain impact of a U.S. government shutdown and evolving EU regulations on PFAS and F-gases add further risk. Given the significant financial losses, persistent legal and environmental liabilities, and governance issues, a seasoned investor would likely recommend selling the stock due to high uncertainty and potential for further downside.

Keywords

Chemicals, Performance Chemicals, Refrigerants, Titanium Dioxide, Fluoropolymers, PFAS, Environmental Remediation, Litigation, SEC Filing, 10-Q, Financial Results, Thermal & Specialized Solutions, Titanium Technologies, Advanced Performance Materials, Corporate Governance, Risk Factors, Sustainability, F-Gas, AIM Act, Goodwill Impairment, Supply Chain Finance, Share Repurchase